Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BRCA1 interacting helicase 1 (BRIP1), also known as FANCJ, is a DNA helicase critical for maintaining genomic stability. As a member of the RecQ DEAH helicase family, it interacts with BRCA1 and participates in homologous recombinational repair. Mutations in BRIP1 are associated with increased risk for ovarian and breast cancer, as well as Fanconi anemia group J. It functions as a tumor suppressor and impacts neuronal health by protecting against oxidative stress.
Inhibition of helicase activity (potential)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BRCA1 Interacting Helicase 1 (BRIP1).